[Primary diffuse large B-cell lymphoma of the uterine cervix - case report].
We present a case of a 54-year-old woman treated for stage IIAE primary diffuse large B-cell lymphoma (DLBCL) of the uterine cervix. The CHOP chemotherapy regimen was started. After the diagnosis of lymphoma of DLBCL CD20+ type was confirmed, rituximab was added to the therapy. Within systemic therapy, the patient received two cycles of CHOP and six cycles of R-CHOP altogether. After treatment completion, total remission of the lesions was observed on computed tomography. Twenty-four months after therapy completion, the patient is disease-free with no signs of recurrence.
Zbigniew J
ZJ
Kojs
maciekniemiec@poczta.onet.pl.
Maciej
M
Niemiec
Barbara
B
Papuga-Fujak
Ewelina
E
Kojs-Pasińska
Włodzimierz
W
Sawicki
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000473:pathology*; D008875:Middle Aged; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology*
chemotherapy; diffuse large B-cell lymphoma; uterine cervix